PLX Key Stats
|Revenue (Quarterly YoY Growth)||-37.68%|
|EPS Diluted (TTM)||-0.2875|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-26.78M|
|Gross Profit Margin (Quarterly)||52.75%|
|Profit Margin (Quarterly)||-171.1%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Protalix BioTherapeutics to Present at Oppenheimer's 24th Annual Healthcare Conference noodls Dec 3
- Protalix BioTherapeutics Inc. Enters Oversold Territory - Tale of the Tape Zacks Nov 27
- Protalix BioTherapeutics Inc. Enters Oversold Territory Nov 27
- Will Omnivision (OVTI) Beat Earnings Estimates? - Analyst Blog Zacks Nov 25
- The Simplest Biotech Growth Portfolio Ever Fool Nov 18
- Maxim Prices Senior Notes - Analyst Blog Zacks Nov 18
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 12
- PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 7
- Protalix BioTherapeutics to Present at Upcoming Scientific and Medical Meetings noodls Oct 31
- Protalix: Undervalued Growth, Plus A Possible Biotech Breakthrough Oct 30
PLX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Protalix BioTherapeutics is down 28.81% over the last year vs S&P 500 Total Return up 27.09%, Biogen Idec up 82.39%, and AEterna Zentaris down 45.74%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for PLX
Pro Report PDF for PLX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download PLX Pro Report PDF
Pro Strategies Featuring PLX
Did Protalix BioTherapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company engaged in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system.